The Global Surrogacy Nexus: Market Demand, Legal Implementation, and Ethical Frontiers

Dr. Tabish Ahmed
Sushrut Hospital and Research Centre

Abstract- The global surrogacy industry has transitioned from a fringe medical procedure to a central pillar of the multi-billion-dollar fertility market. As of 2026, the industry is valued at approximately $32.31 billion, with a projected surge to over $195 billion by 2034. This article provides a comprehensive analysis of the "Surrogacy Nexus," examining the clinical indications and success rates that drive demand, the fragmented legal models of implementation, and the religious and ethical tensions that govern the practice. It specifically synthesizes 2024-2025 data regarding maternal morbidity and neonatal outcomes. The paper concludes by exploring the technological disruption of ectogenesis and advocating for a harmonized international treaty to protect the rights of surrogates, parents, and children born through these arrangements.

Keywords: Gestational Surrogacy, Reproductive Tourism, Bioethics, UFI, Nasab, Ectogenesis, HCCH.

I. INTRODUCTION: THE EVOLUTION OF ASSISTED REPRODUCTION

The desire for biological kinship is a fundamental human drive. However, the path to parenthood has been radically reshaped by technology. In the mid-20th century, surrogacy was primarily "traditional" (using the surrogate's own genetic material). The 1978 breakthrough of *in vitro* fertilization (IVF) enabled "gestational" surrogacy, decoupling the role of the genetic mother from the birth mother.[1]

In the 21st century, this decoupling has created a global marketplace where reproductive labor is traded across borders. With approximately 17.5% of the global adult population experiencing infertility, the demand for surrogacy is no longer a localized phenomenon. It is a response to biological necessity, shifting social norms regarding LGBTQ+ family-building, and the economic realities of a globalized world. This article synthesizes the current state of surrogacy as of 2026, mapping its trajectory from medical treatment to a global socio-legal challenge.

II. CLINICAL INDICATIONS: WHEN SURROGACY IS MEDICALLY NECESSARY

The decision to utilize gestational surrogacy is rarely a first-line choice. It is typically the culmination of a long, often traumatic, reproductive journey. The indications for surrogacy can be broadly categorized into Absolute Medical Indications, Relative Obstetric Indications, and Social/Structural Indications.[2]

2.1 Absolute Medical Indications: The Uterine Factor

Uterine Factor Infertility (UFI) is the primary medical justification for surrogacy. It affects thousands of women worldwide and can be classified into congenital and acquired causes.

- Mayer-Rokitansky-Küster-Hauser (MRKH) Syndrome: A congenital condition where a woman is born without a uterus or with a severely underdeveloped one, though her ovaries typically function normally. For these women, surrogacy (or the emerging field of uterine transplant) is the only path to biological motherhood.
- Hysterectomy: Surgical removal of the uterus due to cervical or uterine cancers, severe endometriosis, or life-threatening postpartum hemorrhage in a previous pregnancy.[3]
- Irreparable Uterine Pathologies: Severe intrauterine adhesions (Asherman's Syndrome) that do not respond to hysteroscopic surgery, or large, multiple fibroids that have distorted the uterine cavity to the point where implantation is impossible.

2.2 Relative Obstetric and Systemic Indications

These indications involve women who have a uterus, but for whom pregnancy poses an "unacceptable risk" to their life or the life of a potential fetus.

- Recurrent Pregnancy Loss (RPL) and Repeated Implantation Failure (RIF): When a patient has undergone multiple IVF cycles with high-quality embryos that fail to implant, or when they have suffered multiple late-term miscarriages without a clear immunological or genetic cause, surrogacy is indicated to "test" if the uterine environment is the primary barrier.
- Critical Maternal Health Conditions: Pregnancy exerts immense strain on the cardiovascular and renal systems. Women with the following conditions are often medically advised against carrying a child:
- Pulmonary Hypertension: Carries a maternal mortality risk of 30–50%.
- Chronic Kidney Disease: Where pregnancy could accelerate the path to dialysis.
- Severe Heart Disease: Such as cardiomyopathy.
- Oncology and Medication Limitations: Women who require ongoing teratogenic medications (drugs that cause birth defects), such as certain treatments for breast cancer or severe autoimmune disorders, may use surrogacy to protect the fetus from drug exposure while maintaining their own life-saving treatment.

2.3 Social and Structural Indications

As social structures evolve, "biological necessity" has expanded to include "structural necessity."[4]

- Single Males and Same-Sex Male Couples: For these individuals, surrogacy is the only biological means of reproduction. The ethical framework here shifts from "healing a malady" to "enabling a fundamental human right to family."
- Age-Related Infertility: While often debated ethically, "social surrogacy" (where a woman chooses surrogacy to avoid the physical toll of pregnancy or due to advanced maternal age) remains a significant driver of demand in commercial markets like the United States and Colombia.

III. CLINICAL OUTCOMES: PREGNANCY COMPLICATIONS AND DELIVERY SUCCESS RATES

The medical efficacy of surrogacy is often contrasted with the biological risks inherent in non-autologous pregnancies. While surrogacy offers high success rates, recent large-scale studies have highlighted specific maternal risks.

3.1 Success Rates: From Transfer to Live Birth

As of 2025, gestational surrogacy paired with high-quality embryos (often PGT-A tested) offers superior success rates.

- Live Birth Rates: In the US, PGT-tested embryos achieve 75–80% live birth rates with experienced carriers.[5]
- Cumulative Success: Success within two transfers often reaches 90-95% in top-tier clinics.

3.2 Maternal Complications: The "Immunological Friction."

Landmark 2024-2025 research indicates that gestational carriers face higher risks of severe maternal morbidity (SMM) than those who conceive naturally or via standard IVF.

- Postpartum Hemorrhage (PPH): The risk of severe PPH is 2.9 times higher for surrogates compared to unassisted conception, with rates reported at approximately 2.36% vs 0.46% in unassisted groups.[6]
- Hypertensive Disorders: Surrogates face a significantly higher risk of severe pre-eclampsia (1.86% compared to 0.42% in natural conception).[7] This "immunological friction" is hypothesized to stem from the carrier's immune response to a completely non-genetic embryo.

3.3 Neonatal Outcomes and Delivery Rates

Neonatal outcomes are generally favorable, though specific variances exist:

- Preterm Birth: Surrogacy has higher rates of preterm birth (<37 weeks) at roughly 10.7-11.5% compared to natural conception (3.1%).[8]
- Birth Weight: Neonates from surrogacy are, on average, 105g lighter than those conceived

spontaneously by the same carrier, though severe neonatal morbidity (SNM) rates remain comparable to IVF births.[9]

IV. GLOBAL IMPLEMENTATION: A COMPARATIVE LEGAL ANALYSIS

The implementation of surrogacy is governed by conflicting national laws, creating a "compliance map" for intended parents.

4.1 The Commercial Model: The United States Case Study

The US represents the "gold standard" of implementation. Through private contracts and "pre-birth orders," intended parents are recognized as legal guardians immediately upon delivery.[10] While secure, the cost is prohibitive, with 2025 programs landing between $150,000 and $250,000.

4.2 The Altruistic Model: The India Case Study

Once the "world's surrogacy capital," India's Surrogacy (Regulation) Act, 2021, now permits only altruistic surrogacy for married Indian citizens.[11] By criminalizing commercial "womb-renting," the law has pushed demand into emerging hubs like Colombia and Mexico.

V. RELIGIOUS AND THEOLOGICAL PERSPECTIVES

Religion plays a foundational role in shaping the "moral architecture" of surrogacy worldwide. Because surrogacy involves the separation of marriage, sex, and procreation, major world religions have developed diverse and often conflicting stances. These perspectives are not merely academic; they directly influence the legislation in countries like Italy, Israel, Saudi Arabia, and Thailand.

5.1 Roman Catholicism: The Argument for Natural Law

The Catholic Church maintains one of the most stringent oppositions to surrogacy. The fundamental document Donum Vitae (The Gift of Life) outlines the Church's stance that procreation must occur within the "conjugal act" of marriage.[12]

- The "Unitive" and "Procreative" Bond: Catholicism argues that surrogacy severs the link between the sexual union of the parents and the birth of the child.
- Dignity of the Person: The Church views surrogacy as a violation of the dignity of the child, arguing that the child becomes an "object" of a contract rather than a "gift" of a loving union. This theological stance is the primary driver behind the total bans on surrogacy in heavily Catholic nations like Italy and the Philippines.

5.2 Islamic Perspectives: Lineage and "Zina."

In Islam, the primary ethical concern regarding surrogacy is the preservation of Nasab (lineage). Islamic jurisprudence varies between Sunni and Shia traditions.[13]

- Sunni Jurisprudence: Most Sunni scholars (such as those at Al-Azhar) consider gestational surrogacy impermissible (haram). The concern is that the introduction of a third party's womb into the reproductive process creates "confusion of lineage." Some scholars liken surrogacy to Zina (adultery), as the surrogate is carrying the genetic material of a man who is not her husband.
- Shia Jurisprudence: Some Shia scholars, particularly in Iran, have issued fatwas allowing gestational surrogacy. They argue that if the embryo belongs to a married couple, the surrogate is merely an "incubator" and no adultery has occurred. This has made Iran a unique hub for surrogacy in the Middle East.

5.3 Judaism: The Primacy of "Be Fruitful and Multiply."

In Jewish law (Halakha), the mandate to procreate is a central commandment. As a result, Jewish perspectives are generally more permissive of Assisted Reproductive Technology (ART).[14]

- Defining Motherhood: A major debate in Halakha is whether "motherhood" is defined by the genetics (egg donor) or the birth (gestational surrogate). Most Israeli rabbinical authorities lean toward the birth mother being the legal mother, but they allow surrogacy to help infertile couples.
- State Implementation: Israel was the first country in the world to implement a state-controlled surrogacy system, reflecting the religious and cultural emphasis on family continuity.

5.4 Hinduism and Buddhism: Intent and Compassion
Eastern religions often approach surrogacy through the lens of Karma and Intent.

- Hinduism: There is no single "official" stance, but many Hindu perspectives are permissive, viewing the help of a surrogate as an act of merit or a way to fulfill the Dharma of householders to have children. However, concerns about the exploitation of the poor (Maya) remain a point of ethical tension.
- Buddhism: Since Buddhism does not have a central creator-god or a strict mandate on procreation, surrogacy is generally seen as a neutral medical tool. The morality depends on the Cetanā (intention). If the surrogate acts out of compassion to help a childless couple, it is viewed positively. If it is purely for greed or involves suffering, it is viewed negatively.

VI. ETHICAL CONSIDERATIONS: THE "THREE-WAY" CONFLICT

The central ethical question is whether surrogacy is a form of labor or exploitation.

- Surrogate Autonomy: Critics argue that in low-income regions, economic necessity acts as a "coercive price," undermining true informed consent.
- Rights of the Child: Cases such as the "Baby Gammy" abandonment highlight the risk of treating children as "commodities" of a contract rather than human subjects.[15]

VII. THE FUTURE: ECTOGENESIS AND ARTIFICIAL WOMBS

By the 2030s, the "human factor" may be disrupted by Ectogenesis.

- Technological Status: 2025-2026 research into fluid-filled "biobags" for premature infants suggests that full ectogenesis (from embryo to term) could eventually eliminate the need for human carriers.[16]
- Policy Response: The Hague Conference on Private International Law (HCCH) is drafting a convention (expected March 2026) to harmonize parentage recognition across borders, aiming to end the era of "stateless" children.[17]

VIII. CONCLUSION

Surrogacy is a testament to human longing and scientific progress, but its implementation remains a fragmented "wild west." To protect all parties, the global community must transition toward an international standard. This includes independent legal representation for surrogates, universal minimum compensation to prevent exploitation, and the automatic recognition of parentage across borders. The path to parenthood should be built on ethical innovation, not the exploitation of economic vulnerability.

REFERENCES

[1] Katarina Trimmings & Sharon Shakargy (eds.), *Research Handbook on Surrogacy and the Law* 8 (Edward Elgar, 2024).
[2] Sambhu Charan Mondal, et. al., "Genetic and Gestational Surrogacy: an Overview", 9 *Walailak J. Sci. & Tech.* 189 (2012).
[3] WHO, *Global Infertility Prevalence Rates* (Report, 2023).
[4] Mordor Intelligence, *Surrogacy Market Analysis 2025-2030* (2025).
[5] EDSI, *2025 U.S. Surrogacy Outlook: Costs, Laws, and Trends* (2025).
[6] Nicola Davis, "Surrogates face higher risk of pregnancy complications, study finds", *The Guardian*, Sept. 23, 2024.
[7] Maria P. Velez, et. al., "Severe Maternal and Neonatal Outcomes Among Gestational Carriers", 181 *Annals of Internal Medicine* (2024).
[8] "Surrogates have higher risk of pregnancy complications, research finds", *The BMJ*, 386:q2100 (2024).
[9] Perinatal outcomes after natural conception vs IVF in gestational surrogates, 108 *Fertility and Sterility* (2017/Updated 2024).
[10] Sital Kalantry, "Surrogacy in the USA" in *Research Handbook on Surrogacy and the Law* 437 (2024).
[11] The Surrogacy (Regulation) Act, 2021 (India), s. 4.
[12] *Donum Vitae*, Instruction on Respect for Human Life (1987).
[13] Nensi Sinanaj, "Surrogacy and discrimination" in

Research Handbook on Surrogacy and the Law 130 (2024).
[14] Claire Fenton-Glynn, *Surrogacy, Law and Human Rights* 40 (Ashgate, 2016).
[15] David Smolin, "Surrogacy, intermediaries, and the sale of children", 54 *Int'l J. Law Policy Family* (2024).
[16] A. Smajdor, "The Moral Imperative for Ectogenesis", 47 *J. Med. Ethics* (2021).
[17] Laura Martínez-Mora, "Surrogacy and the Hague Conference" (HCCH Report, Nov. 2025).

Bibliography

- HCCH, *Working Group on Parentage/Surrogacy Final Report* (2025).
- IMARC Group, *Surrogacy Market Size, Trends and Forecast 2026-2034* (2025).
- Precedence Research, *Surrogacy Market Size to Reach USD 195.97 Billion by 2034* (2024).
- Velez, M.P., et. al., "Severe Maternal and Neonatal Outcomes Among Gestational Carriers: A Population-Based Cohort Study", *Annals of Internal Medicine* (2024).